Explore

Rapid Read Rapid Read
Former Senator Ben Sasse Praises Daraxonrasib for Tumor Reduction

Former Senator Ben Sasse Praises Daraxonrasib for Tumor Reduction

Former U.S. Senator Ben Sasse has publicly praised a new drug, daraxonrasib, for significantly reducing his pancreatic cancer tumors. In an interview with CBS News' 60 Minutes, Sasse revealed that the drug has shrunk his tumor volume by more than three-quarters over the past four months. Daraxonrasib, developed by Revolution Medicines, is currently in Phase 3 clinical trials and targets RAS-connected cancers. It is the first drug of its kind to inhibit RAS proteins, which are known to influence the development of various cancers, including pancreatic cancer. Sasse, who was diagnosed with pancreatic cancer last year, expressed hope that the drug could extend his life beyond the initial prognosis of three to four months.
Trendline Trendline
Dark Horse Consulting and Porton Advanced Sign MOU to Facilitate IITs in China

Dark Horse Consulting and Porton Advanced Sign MOU to Facilitate IITs in China

Dark Horse Consulting and Porton Advanced Sign MOU to Facilitate IITs in China
Trendline Trendline
U.S. Faces Challenges in Biotech Race Against China, Highlights Innovation and Regulatory Hurdles

U.S. Faces Challenges in Biotech Race Against China, Highlights Innovation and Regulatory Hurdles

U.S. Faces Challenges in Biotech Race Against China, Highlights Innovation and Regulatory Hurdles
Reuters Reuters
Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet

Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet

By Christy Santhosh April 27 (Reuters) - Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline.
Rapid Read Rapid Read
Former Senator Ben Sasse Credits 'Miracle Drug' for Extending Life Amid Pancreatic Cancer Battle

Former Senator Ben Sasse Credits 'Miracle Drug' for Extending Life Amid Pancreatic Cancer Battle

Former Republican Senator Ben Sasse has publicly shared his battle with stage 4 pancreatic cancer, revealing that a 'miracle drug' under review by the Food and Drug Administration (FDA) has significantly improved his condition. Diagnosed in December, Sasse was initially given a prognosis of three to four months to live. However, during an interview on '60 Minutes,' he credited the drug, daraxonrasib, for reducing his tumor volume by 76% and alleviating his pain. The drug, developed by Revolution Medicines, targets a mutation in the KRAS gene, which is prevalent in over 90% of pancreatic cancer cases. This targeted therapy is believed to offer treatment with less toxicity compared to traditional chemotherapy. The FDA is currently reviewing the drug, with a potential expedited approval process due to a new federal pilot program.
Trendline Trendline
Xcovery and EVERSANA Partner to Launch Lung Cancer Drug Ensacove in U.S.

Xcovery and EVERSANA Partner to Launch Lung Cancer Drug Ensacove in U.S.

Xcovery and EVERSANA Partner to Launch Lung Cancer Drug Ensacove in U.S.
Rapid Read Rapid Read
Alterity Therapeutics Advances Toward Phase 3 Trial for MSA Treatment

Alterity Therapeutics Advances Toward Phase 3 Trial for MSA Treatment

Alterity Therapeutics has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its Phase 3 development program for ATH434, a treatment for Multiple System Atrophy (MSA). This feedback follows a Type C Meeting with the FDA, focusing on the chemistry, manufacturing, and control elements of the program. MSA is a rare neurodegenerative disease with no approved disease-modifying treatments. The FDA's endorsement of Alterity's manufacturing plans is a critical step toward initiating the Phase 3 trial. Alterity aims to finalize its plans with the FDA at an End-of-Phase 2 meeting scheduled for mid-2026.
Rapid Read Rapid Read
Former Senator Ben Sasse Attributes Extended Life to Experimental Cancer Treatment

Former Senator Ben Sasse Attributes Extended Life to Experimental Cancer Treatment

Former U.S. Senator Ben Sasse, diagnosed with stage 4 metastatic pancreatic cancer, credits an experimental drug for extending his life beyond initial expectations. Diagnosed in December and given a prognosis of three to four months, Sasse has seen a 76% reduction in tumor size due to a clinical trial involving the drug daraxonrasib. This treatment, developed by Revolution Medicines, has extended the life expectancy of patients from six to approximately thirteen months. Sasse discussed his journey and the impact of this treatment in an interview with Scott Pelley on '60 Minutes,' highlighting the role of faith and medical innovation in his ongoing battle with cancer.
Rapid Read Rapid Read
Former Senator Ben Sasse Credits Miracle Drug for Extending Life Amid Cancer Battle

Former Senator Ben Sasse Credits Miracle Drug for Extending Life Amid Cancer Battle

Former U.S. Senator Ben Sasse, diagnosed with stage 4 metastatic pancreatic cancer, has experienced a significant extension of life due to a clinical trial drug. Initially given only a few months to live, Sasse attributes his extended survival to 'providence, prayer, and a miracle drug' that has reduced his tumors by 76%. The drug, daraxonrasib, developed by Revolution Medicines, has shown promise in extending the lives of patients with similar diagnoses. Sasse discussed his health journey and the state of American politics in an interview with Scott Pelley on '60 Minutes,' expressing concerns about the lack of long-term vision in Congress.
Trendline Trendline
CatalYm Initiates Phase 2/3 Trial for Visugromab in Cancer Cachexia Treatment

CatalYm Initiates Phase 2/3 Trial for Visugromab in Cancer Cachexia Treatment

CatalYm Initiates Phase 2/3 Trial for Visugromab in Cancer Cachexia Treatment
Trendline Trendline
Arrowhead Pharmaceuticals Gains Positive CHMP Opinion for REDEMPLO in Europe, Targeting FCS Treatment

Arrowhead Pharmaceuticals Gains Positive CHMP Opinion for REDEMPLO in Europe, Targeting FCS Treatment

Arrowhead Pharmaceuticals Gains Positive CHMP Opinion for REDEMPLO in Europe, Targeting FCS Treatment
Rapid Read Rapid Read
GE HealthCare Initiates Phase 2/3 Trial for Manganese-Based MRI Contrast Agent with FDA Fast Track Designation

GE HealthCare Initiates Phase 2/3 Trial for Manganese-Based MRI Contrast Agent with FDA Fast Track Designation

GE HealthCare has announced the dosing of the first patient in the Phase 2/3 LUMINA clinical trial for its manganese-based MRI contrast agent, mangaciclanol, at the Mayo Clinic in Rochester, Minnesota. This investigational agent, which has received Fast Track designation from the U.S. Food and Drug Administration (FDA), is being developed as a potential alternative to gadolinium-based MRI contrast agents. Mangaciclanol aims to enhance the visualization of abnormal structures during MRI procedures, offering comparable diagnostic capabilities to existing gadolinium-based agents. Unlike gadolinium, manganese is a naturally occurring element in the body, which may reduce concerns about retention and environmental impact.